Clinical Trial Update: Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload [Phase 2]

View source ↗

Summary

Phase 2 trial of deferasirox for iron overload in patients who underwent allogeneic stem cell transplant was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Overload

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2019-05-29